|
US2016106812A1
|
|
Treatment of cancer with immune stimulators
|
|
US2013296223A1
|
|
Use of thymosin alpha for the treatment of sepsis
|
|
CN104507491A
|
|
Use of thymosin alpha for treatment of purulent rhinosinusitis
|
|
EP2675272A1
|
|
Thymosin alpha peptide for preventing, reducing the severity of, and treating infection
|
|
WO2012068412A2
|
|
Method and compositions for treatment of stat3-responsive cancers and/or renal cancer
|
|
WO2012040656A2
|
|
Biomarkers to track response to scv-07
|
|
US2011245316A1
|
|
Prevention or delay of onset of oral mucositis
|
|
US2010311656A1
|
|
Treatment or prevention of respiratory viral infections with alpha thymosin peptides
|
|
CN102458470A
|
|
Alpha thymosin peptides as vaccine enhancers
|
|
CA2733518A1
|
|
Treatment or prevention of hepatitis c with immunomodulator compounds
|
|
AU2008335025A1
|
|
Treatment of melanoma with alpha thymosin peptides in combination with a kinase inhibitor
|
|
AU2008338594A1
|
|
Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (HSAA)
|
|
AU2008335840A1
|
|
Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic T lymphocyte-associated antigen 4 (CTLA4)
|
|
NZ584065A
|
|
Treatment of lung cancer with scv-07
|
|
WO2008143824A1
|
|
Treatment of allergic disease with immunomodulator compounds
|
|
CA2677749A1
|
|
Method of treating or preventing tissue deterioration, injury or damage due to disease of mucosa
|
|
AU2008200190A1
|
|
Method of Administering a Thymosin Alpha 1 Peptide
|
|
US2008300166A1
|
|
Treatment of Melanoma with Alpha Thymosin Peptides
|
|
CA2649575A1
|
|
Treatment of melanoma
|
|
JP2006232862A
|
|
Composition for treating patient of decompensation hepatic failure
|
